A Pharmacokinetics (PK) Study in Healthy Adults

Summary

This is to characterize STN1013800 active ingredient bioavailability following multiple-dose ocular administration of STN1013800 to both eyes in healthy adults. It is a PK study with screening period of up to 28 days + dosing period of 7 days + Follow-up period of 2 days. At present, there are no medicines for the treatment of acquired blepharoptosis in China. Therefore, efficacy and safety phase III study is also currently being conducted.

Timeline

Start

2025-03-17

Primary completion

2025-04-07

Completion

2025-04-07

Drugs

Indications